Equity
€512,923 ▲ 22.1%
PHARMALEC has made a profit in every financial year since 2018.
PHARMALEC
Lifetime
8 annual accounts with figures on one time axispeak €185,768 (2023)
€157,277▲ 10.8%
peak €115,521 (2023)
€92,828▲ 17.2%
peak €512,923 (2025)
€512,923▲ 22.1%
€1.3m▼ 8.4%
Board1 name since 2021
1 directorGHIJSELINGS Andreas
Documentsfilings and deeds
30-07-20261 day before the deadline
2025micro format
Equity from €420,094 to €512,923Investments €7,904Cash from €16,319 to €1,458
Key points
from the 2025 annual accountsTurnover
≈ €230,000 estimated
The micro format states no turnover.
Debts
€1.3m 72% of the balance sheet
Financial debts 74%Suppliers 0%Taxes and wages 2%Other 25%
Of this, €342,156 falls due within a year.
Investments
€7,904 2.1 × depreciation
Green is investment, beige is depreciation.
Filings
8 annual accounts 4 late
The 2022 accounts came latest: 31 days after the end of the period.
Position in the sector
€92,828
Higher net result than 90% of companies in real estate. Sector median €5,994 · 17,181 companies.
Checked score
83
Excellent
Financially stronger than 57% of micro companies in real estate (NACE 68)
Probability in this band: under 0.55%
Bankruptcy probability within 12 months
0.5% Very low
0%0.5%1.5%4%10%≥ 25%
The dashed line is the sector median: 0.2% across 26,625 companies (NACE 68, micro).
About 5 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: 0.2%
01-2025: 0.2%● unchanged vs 12-2024lowest value
02-2025: 0.2%● unchanged vs 01-2025
03-2025: 0.2%● unchanged vs 02-2025
04-2025: 0.2%● unchanged vs 03-2025
05-2025: 0.2%● unchanged vs 04-2025
06-2025: 0.3%▲ +0.1 percentage points vs 05-2025
07-2025: 0.3%● unchanged vs 06-2025
08-2025: 0.6%▲ +0.3 percentage points vs 07-2025highest value
09-2025: 0.3%▼ -0.3 percentage points vs 08-2025
10-2025: 0.3%● unchanged vs 09-2025
11-2025: 0.3%● unchanged vs 10-2025
12-2025: 0.3%● unchanged vs 11-2025
01-2026: 0.3%● unchanged vs 12-2025
02-2026: 0.3%● unchanged vs 01-2026
03-2026: 0.3%● unchanged vs 02-2026
04-2026: 0.3%● unchanged vs 03-2026
05-2026: 0.3%● unchanged vs 04-2026
06-2026: 0.3%● unchanged vs 05-2026
07-2026: 0.4%▲ +0.1 percentage points vs 06-2026
08-2026: 0.5%▲ +0.1 percentage points vs 07-2026
09-2026: 0.5%● unchanged vs 08-2026
10-2026: 0.5%● unchanged vs 09-2026
11-2026: 0.5%● unchanged vs 10-2026
Financial strengthAverage
Score breakdown
raises risk
Liquidity: current ratio 0.26, cash €1,458, halved
lowers risk
Sector: Real estate activities (NACE 68)
Size: total assets €1.8m
Figures for financial year 2025 (filed on 01-08-2026)
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 68, micro). It does better than 48% of them on solvency, 39% on liquidity, 64% on profitability and 77% on growth.
The bankruptcy probability was computed on 08-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 31-12-2025.
Of the companies with a bankruptcy probability in the very low class on 30-06-2025, 0.1% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Credit verdict
Credit of up to €40,000 on 30-day terms is acceptable
Liquidity is insufficient, with a current ratio of 0.26 (0.33 in 2024), below 1. Short-term debt is 18.9% and cash 0.1% of total assets. 71.6% of the assets are financed with debt and provisions.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Five signals.
lowers riskraises riskneutral
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 30-07-2026, 1 day ahead of the deadline.
NBB · 8 filingsDeviation from the deadline
2025
1 day early
2024
28 days late
2023
37 days early
2022
31 days late
2021
26 days late
2020
17 days early
2019
7 days early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 7 accounts on average 3 days after the deadline. In the sector (NACE 68), the median for financial year 2024 was 7 days before the deadline, and 36% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 26 August (4 of the last 5 accounts filed within 30 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
09-11-2026 today31-12-2026 year end31-07-2027 deadline
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0678956844
Change of role: GHIJSELINGS Andreas, from manager to director
Director discharge: GHIJSELINGS Andreas · General meeting of 28-01-2021 · Gazette deed
First establishment
Pharmalec BVBA, Lenneke Marelaan 34, Zaventem
Incorporation
published on 01-08-2017 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| PHARMALEC Zaventem | €1.8m | €157,277 | 28.4% | - |
| MSE Invest Grimbergen | €1.8m | €148,423 | 23.1% | - |
| ROAS INVEST Beersel | €1.8m | €135,701 | 1.6% | - |
| YUNIDI INVEST Dilbeek | €1.7m | €168,470 | 12.3% | - |
| Tilo Overijse | €1.7m | €130,182 | 90.7% | - |
| CIMAZUR Leuven | €2.1m | €138,778 | 10.7% | - |
| SEMPELS PROJECTS Lubbeek | €1.6m | €195,510 | 4.6% | 0 |
These companies have the same main activity as PHARMALEC: renting and operating of own or leased residential real estate, excluding social housing (NACE 68201). They are comparable in size and age: total assets between €1.6m and €2.1m, founded between 2017 and 2018.
Official details
Source: KBO- Status
- Active since 28-07-2017Normal situation
- Activity
- Renting and operating of own or leased residential real estate, excluding social housingNACE 68201and 1 other
- Establishment unit
- 2.285.728.5861932 Zaventem, since 01-10-2017
- Financial year end
- 31 December
- Peppol
- Reachable since 10-01-2025
Annual accounts 2025
- €1.8m▼ 1.4%
- Filing
- Filed on 30-07-2026, 1 day before the end of the filing period
Insights on PHARMALEC
PHARMALEC files the micro format. That format states no turnover. The gross margin rose from €61,692 in 2018 to €157,277 in 2025.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about PHARMALEC
- What is the company number of PHARMALEC?
- The company number of PHARMALEC is 0678.956.844. The VAT number is the same number with BE in front: BE 0678.956.844.
- Where is PHARMALEC based?
- The registered office is at Lenneke Marelaan 34, 1932 Zaventem.Company details
- What does PHARMALEC do?
- According to the KBO register, the main activity is renting and operating of own or leased residential real estate, excluding social housing (NACE 68201).
- What is the legal form of PHARMALEC?
- PHARMALEC is a private limited company (BV).
- When was PHARMALEC founded?
- PHARMALEC was founded on 28-07-2017.
- Is PHARMALEC still active?
- Yes, PHARMALEC is an active enterprise in the KBO register.
- What is the turnover of PHARMALEC?
- The turnover in financial year 2025 is ≈ €230,000. This figure is estimated from the gross margin of €157,277 and 31 comparable companies (NACE 68201). It probably lies between €180,000 and €310,000.Financials
- Is PHARMALEC profitable?
- In financial year 2025, PHARMALEC made a profit of €92,828.
- Where can I find the annual accounts of PHARMALEC?
- PHARMALEC filed 8 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of PHARMALEC due?
- PHARMALEC must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.